Altogether, the data demonstrated the utility of CRISPR/Cas9 screens to uncover mechanisms underlying the sensitivity to DNT therapy and suggests CD64 as a predictive marker for response in AML patients (Hsu et al., 2013). This evidence concerns the gene FCGR1A and acute myeloid leukemia.